The Bulletin
The Times


.

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

  • Written by PR Newswire
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
  • Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D
  • Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline

SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong...

The Bulletin Magazine

Executive Recruitment for Education Leadership: What Schools Should Consider

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

hacklink zlibraryzlibraryz-libraryvippark kayıtPadişahbetjustin tvvaycasino girişPadişahbettaraftarium24Sahabetjojobetjojobetjojobetviljo kasinot kirjautuminenGalabetzimpler kasinotGalabet1xbetjojobetcasibomcasibomjojobettaraftarium24taraftariumjojobetjojobetmeritkinghacklink panel